ADVANCED HEPATOCELLULAR CARCINOMA

This early-stage study is testing a new drug called ALN-BCAT, both by itself and combined with an existing immunotherapy (pembrolizumab), for people with advanced liver cancer that has spread. The main goals are to find safe doses and see how well the body handles the treatment. …

This study is testing whether adding a precise, high-dose radiation treatment (SBRT) to standard immunotherapy drugs helps people with advanced liver cancer live longer. About 252 participants with liver cancer that has spread into major blood vessels will receive either immunoth…

This is the first human study of an experimental oral medication called AU409 for people with advanced liver cancers or other solid tumors that have spread to the liver. The main goal is to find the safest and most effective dose by testing it in a small group of patients whose c…

This study is testing whether combining two drugs, sapanisertib and cabozantinib, works better than cabozantinib alone for people with advanced liver cancer that has a specific genetic mutation called β-catenin. The main goals are to find the safest dose of the combination and to…

This Phase 3 trial is testing whether a drug called ADI-PEG 20 can help people with advanced liver cancer that cannot be surgically removed. The study will compare the drug against a placebo in 300 participants who have high levels of a natural substance called arginine in their …

This early-stage trial is testing the safety of combining a wearable device that uses electric fields to disrupt cancer cells with different drug combinations. It is for adults with advanced cancers in the abdomen or chest that have spread and who have run out of standard treatme…

This study is testing whether giving standard cancer treatments at home is as safe and effective as giving them in a clinic. It aims to see if receiving care at home reduces stress, improves quality of life, and is preferred by patients with advanced cancers. About 220 participan…

This is an early-stage study to test the safety and initial effectiveness of a new personalized cell therapy called CNCT19 for advanced liver cancer. Doctors will collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. The ma…

This study is testing whether a combination of two immunotherapy drugs, ligufalimab and cadonilimab, can help control advanced liver or bile duct cancers that have worsened after prior immunotherapy. It will enroll about 64 adults whose cancer has spread and is no longer respondi…

This study is testing if a short, intense course of radiation followed by immunotherapy drugs can help control advanced liver cancer that has spread. The goal is to see if this combination helps the body's immune system better recognize and attack the cancer. It is for adults who…

This study is testing whether adding celecoxib, a common anti-inflammatory pain medication, can help two immunotherapy drugs work better against advanced liver cancer that has spread. The goal is to see if this combination can better control the cancer's growth and spread. Resear…

This is a first-in-human study to test the safety and initial effectiveness of a new drug called BGB-B2033. It will be given alone or in combination with other cancer drugs to people with specific advanced or metastatic solid tumors, including certain liver, lung, stomach, and ge…

This study is testing a new drug called PF-08634404 to see if it is safe and effective for treating advanced liver cancer that cannot be removed by surgery. It will be given alone or combined with another drug (ipilimumab) to 138 adults who have not had other whole-body treatment…